Home » MEDCAC Fails to Vote on ESAs for Kidney Transplants
MEDCAC Fails to Vote on ESAs for Kidney Transplants
A lack of evidence led the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) to avoid voting on whether erythropoiesis-stimulating agents (ESAs) are necessary to improve renal transplant graft survival in patients with chronic kidney disease as the Centers for Medicare & Medicaid Services decides whether to cover the drugs. The committee did vote that panel reactive antibody assays, which measure anti-human antibodies in the blood, predict renal transplant graft survival. This has been cited as an argument that ESAs increase survival following kidney transplant.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
07May
-
14May
-
30May